| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/18/2002 | WO2001068569A3 Il-8 receptor antagonists |
| 04/18/2002 | WO2001066595A3 Human fgf-23 gene and gene expression products |
| 04/18/2002 | WO2001060377A3 Methods for treatment of lysosomal storage diseases using biphosphonates |
| 04/18/2002 | WO2001060345A3 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator |
| 04/18/2002 | WO2001058916A3 Antibodies to ccr5 |
| 04/18/2002 | WO2001058483A3 METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES |
| 04/18/2002 | WO2001056601A3 Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| 04/18/2002 | WO2001051080A3 Methods and compositions for obtaining disease protection for animals |
| 04/18/2002 | WO2001049743A3 Methods of modulation of the immune system |
| 04/18/2002 | WO2001026656A3 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors |
| 04/18/2002 | WO2001025437A3 Growth factor polypeptides and nucleic acids encoding same |
| 04/18/2002 | WO2000067793A9 Death domain containing receptor 4 |
| 04/18/2002 | WO2000066106A9 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 04/18/2002 | US20020045765 Tocopherol derivatives and method for preparation thereof |
| 04/18/2002 | US20020045642 Antiinflammatory, -arthritic and -emetic agents; central nervous system disorders; Parkinson's disease; antidepressants; psychological disorders; anxiolytic agents; antagonists of substance P receptors |
| 04/18/2002 | US20020045623 Stable; potent; penetrates cell membranes; effectively hinders cellular apoptosis; Antiinflammatory agents, Ischemic agents, cancer, autoimmune diseases and nervous system disorders. |
| 04/18/2002 | US20020045601 Ophthalmic compositions |
| 04/18/2002 | US20020045587 Attenuated bacteria transformed with a promoter activated in cytosol of a host cell to produce a polypeptide lethal to the bacterium, and a host cell compatible promoter coding for therapeutic polypeptide such as an antigen; vaccination |
| 04/18/2002 | US20020045575 Treating inflammatory, autoimmune diseases, including graft-versus-host disease and enhancement of graft/tissue survival following transplant |
| 04/18/2002 | US20020045213 IL-17 receptor like molecules and uses thereof |
| 04/18/2002 | US20020045203 Method for detecting active ingredients of medical value |
| 04/18/2002 | US20020044977 Centipeda plant extract |
| 04/18/2002 | US20020044967 Sustained release preparations |
| 04/18/2002 | US20020044947 Powdered mixture of Hericium, Radix Astragali, Cordyceps Sinensus, Radix Glycyrrhizae and Dioscoreae Oppositae; enhanced production of Interleukin-1 beta without increasing production of Interleukin-4 |
| 04/18/2002 | US20020044944 DNA encoding the polypeptide, with at least one deletion in the amino acid sequence; expression vectors; host cells; higher apoptosis activity |
| 04/18/2002 | US20020044940 Novel saponin compositions and uses thereof |
| 04/18/2002 | US20020044924 Extracorporeal treatment of the patient's blood cells to induce apoptosis and administration of the apoptotic bodies and/or cells to patient; T-cell- mediated and inflammatory disorders |
| 04/18/2002 | US20020044923 Modulating immune responses using antigen presenting human mesenchymal stem cells to induce specific T cell anergy |
| 04/18/2002 | CA2462681A1 Disease prevention by reactivation of the thymus |
| 04/18/2002 | CA2462671A1 Normalization of defective t cell responsiveness through manipulation of thymic regeneration |
| 04/18/2002 | CA2462073A1 Hematopoietic stem cell gene therapy |
| 04/18/2002 | CA2462046A1 Improvement of graft acceptance through manipulation of thymic regeneration |
| 04/18/2002 | CA2462027A1 Stimulation of thymus for vaccination development |
| 04/18/2002 | CA2425818A1 Novel human beta2 integrin alpha subunit |
| 04/18/2002 | CA2425815A1 Treatment of t cell disorders |
| 04/18/2002 | CA2425581A1 Modulation of ligand binding/enzymatic activity of alpha beta proteins |
| 04/18/2002 | CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | CA2424967A1 Complexes for transferring nucleic acids into cells |
| 04/18/2002 | CA2424951A1 Beta-amino acid derivatives as integrin receptor antagonists |
| 04/18/2002 | CA2424379A1 Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| 04/18/2002 | CA2424292A1 Tricyclic compounds and uses thereof |
| 04/18/2002 | CA2423515A1 Pyrazole derivatives for the treatment of viral diseases |
| 04/18/2002 | CA2394084A1 Inhibitors of protein kinases |
| 04/17/2002 | EP1197484A2 1H-Indole-3-glyoxylamide sPLA2 inhibitors |
| 04/17/2002 | EP1197225A1 REMEDIES FOR DISEASES CAUSED BY PTH OR PTHrP |
| 04/17/2002 | EP1197218A1 Algae protein polysaccharide extraction and use thereof |
| 04/17/2002 | EP1197210A1 Agents inhibiting chronic rejection reactions after organ transplantation |
| 04/17/2002 | EP1196772A2 Induction of a th1-like response in vitro |
| 04/17/2002 | EP1196635A2 Cell death related drug targets in yeast and fungi |
| 04/17/2002 | EP1196598A1 Dsp-3 dual-specificity phosphatase |
| 04/17/2002 | EP1196579A2 Tryptase inhibitor |
| 04/17/2002 | EP1196577A2 Cell cycle and proliferation proteins |
| 04/17/2002 | EP1196575A2 Gtp-binding protein associated factors |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196569A2 Electron transfer proteins |
| 04/17/2002 | EP1196567A2 Human immune response molecules |
| 04/17/2002 | EP1196565A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 04/17/2002 | EP1196558A1 Immunostimulant oligonucleotide |
| 04/17/2002 | EP1196543A2 Treatment of dendritic cells for induction of immune tolerance |
| 04/17/2002 | EP1196450A1 Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis |
| 04/17/2002 | EP1196441A1 Keratinocyte growth factor-2 |
| 04/17/2002 | EP1196440A2 Therapeutic peptides derived from subsequences of bpi |
| 04/17/2002 | EP1196419A1 Potassium channel blocking agents |
| 04/17/2002 | EP1196414A1 Prodrugs of carbamate inhibitors of impdh |
| 04/17/2002 | EP1196407A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 04/17/2002 | EP1196404A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 04/17/2002 | EP1196391A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 04/17/2002 | EP1196390A2 Pyrazole compositions useful as inhibitors of erk |
| 04/17/2002 | EP1196373A1 3-amino-2-benzyl-1-phenyl-propane derivatives |
| 04/17/2002 | EP1196193A2 Interleukin-1 muteins useful as vaccine adjuvants |
| 04/17/2002 | EP1196192A1 Method for enhancing an immune response |
| 04/17/2002 | EP1196191A1 Death domain containing receptor 5 |
| 04/17/2002 | EP1196182A2 Method for enhancing production performance in an animal |
| 04/17/2002 | EP1196180A1 Treatment of angiogenesis dependent conditions with dextrin sulphate |
| 04/17/2002 | EP1196178A1 Covalently closed immunostimulating nucleic acid molecule |
| 04/17/2002 | EP1196174A1 Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis |
| 04/17/2002 | EP1196169A1 Compounds having cytokine inhibitory activity |
| 04/17/2002 | EP1196129A1 Method for scavenging radicals with urocanic acid, derivatives and analogues |
| 04/17/2002 | EP1196047A1 Prophylactic dietary supplement based on milk |
| 04/17/2002 | EP1196031A1 Vaccine formulations and methods for immunizing an individual against shed antigen-specific b cells |
| 04/17/2002 | EP0937038B1 Vitamin d analogues |
| 04/17/2002 | EP0934290B1 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same |
| 04/17/2002 | EP0901378B1 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid |
| 04/17/2002 | EP0880519B1 Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them |
| 04/17/2002 | EP0740550B1 Use of mometasone furoate for treating airway passage and lung diseases |
| 04/17/2002 | EP0660708B1 Phospholipids |
| 04/17/2002 | EP0359783B2 Treatment of autoimmune diseases by oral administration of autoantigens |
| 04/17/2002 | CN1345374A HER-2/neu fusion proteins |
| 04/17/2002 | CN1345336A Antibody and chemokine constructs and their use for treating autoimmune diseases |
| 04/17/2002 | CN1345332A C-terminal modified (N-substituted)-2 indolylcarbonyldiptides as inhibitors of ICE/CED-3 family of cysteine proteases |
| 04/17/2002 | CN1345331A Method and composition for angiogenesis inhibition |
| 04/17/2002 | CN1345329A Tumor mecrosis factor receptors 6 alpha and beta |
| 04/17/2002 | CN1345317A (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for production thereof and pharmaceutical compositions containing the same |
| 04/17/2002 | CN1345314A Amine derivatives as protease inhibitors |
| 04/17/2002 | CN1345308A Acetylenic alpha-amino acid based sulfonamide hydroxamic acid TACE inhibitors |
| 04/17/2002 | CN1345307A N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 04/17/2002 | CN1345244A Herbal compositions and uses for treatment tof allergic reactions |
| 04/17/2002 | CN1345239A Heterocyclic containing biphenyl alpha P2 inhibitors and method |
| 04/17/2002 | CN1345189A Nutritional compositions with contain slightly negatively charged, non-digestible polysaccharides and use thereof for reducing transport through tight junctions |
| 04/17/2002 | CN1344755A Prep. of degradable polymer, pharmaceutical composition containing the same and its use |